The House of Brands, Coming Off Its Best Year Yet

Honasa Consumer is India’s largest digital-first beauty and personal care (BPC) company by revenue, built around Mamaearth and a portfolio of newer brands — The Derma Co., Aqualogica, BBlunt, Dr Sheth’s and Staze — spanning skincare, haircare, baby care and colour cosmetics.

The core Mamaearth brand, after a multi-quarter slowdown through FY24–FY25, has returned to double-digit growth on refreshed formulations and sharper Gen-Z-oriented marketing. The Derma Co. has emerged as the group’s standout performer, crossing an annualised NSV run-rate of over ₹1,000 crore and entering double-digit EBITDA margins in its own right. The younger brands and BTM Ventures collectively provide the next leg of the portfolio, growing over 25–40% and increasingly de-risking the group away from single-brand dependence.

Distribution has diversified meaningfully beyond D2C and marketplaces (Amazon, Flipkart) into quick commerce, and — more recently — general and modern trade, which now covers roughly 3 lakh FMCG retail outlets and is growing over 40% YoY. Management’s FY31 ambition, laid out at its June 2026 Investor Day, targets ₹5,500 crore of revenue, implying an ~18% revenue CAGR from the FY26 base alongside continued EBITDA margin expansion of roughly 100 bps a year.

From Loss-Making Scale-Up to Genuine Profitability

FY26 marked an inflection point — revenue grew 16% while EBITDA nearly tripled and EBITDA margin expanded from 3.3% to 9.7%, on the back of operating leverage and a moderating advertising-to-sales ratio. Q1 FY27 has extended this sharply: revenue +27% YoY, EBITDA +141% YoY and PAT +117–119% YoY, with EBITDA margin at 14.6% — the highest in the company’s listed history.

Note: FY23 EBITDA reflects pre-IPO ESOP/exceptional charges; figures rounded and drawn from company filings and exchange disclosures. Q1 FY27 shown as a standalone quarter, not annualised.

Ten-Year Discounted Cash Flow

We model a 10-year FCFF DCF off the FY26 revenue base of ₹2,392 crore, fading growth from 28% in FY27E toward a 5% terminal rate, with EBITDA margin expanding from ~12% to ~17.8% by the terminal year — broadly in line with management’s own 100 bps/year margin-expansion guidance and its FY31 revenue ambition. We use a WACC of 12% (reflecting small-cap, single-category consumer-brand risk) and a 5% terminal growth rate.

Even at the most favourable end of a reasonable assumption range (11% WACC, 6% terminal growth), the DCF tops out near ₹346 — well short of the ₹479 CMP. Closing that gap requires either a growth runway meaningfully longer than 10 years, terminal margins above 18%, or a market willingness to price optionality (new brands, international expansion) that isn’t yet in the visible numbers.

Priced More Like a Growth Story Than an FMCG Compounder

Honasa has no clean listed peer — it sits between digital-first BPC platforms (FSN E-Commerce/Nykaa) and traditional FMCG majors. On trailing P/E it trades at a steep premium to staples despite far higher earnings volatility, and roughly in line with — or above — Nykaa on EV/Sales despite a narrower category focus.

Peer multiples are indicative, sourced from recent market data; large-cap FMCG peers are structurally higher-margin and lower-growth, so multiples are not directly comparable — shown for context on where the market is pricing brand-led consumer businesses broadly.

The read-through: Honasa trades at a P/E well above mature FMCG names that generate 2x its EBITDA margin, and at an EV/Sales multiple comparable to Nykaa despite Nykaa’s larger multi-category platform. The market is effectively underwriting Honasa’s margin-expansion story reaching FMCG-like profitability (18–20%+ EBITDA margin) years before the current run-rate suggests it will.

An Asset-Light Balance Sheet — Value Sits in the Brand, Not the Assets

Honasa is asset-light by design (outsourced manufacturing, digital-first distribution), so book value is a poor proxy for intrinsic worth. The balance sheet is clean: total equity of ~₹1,125 crore, debt of only ~₹139 crore, and cash & short-term investments of ~₹663 crore, leaving net cash of ~₹524 crore. Trading at ~10.8x book value, the stock is priced almost entirely on brand equity, distribution reach and future earnings power rather than tangible assets.

Stripping Out Growth: What Is the Business Worth Today?

EPV values the business on its current, normalised earning power alone — no credit for future growth. Using TTM revenue of ~₹2,553 crore and TTM EBITDA margin of ~11.8%, normalised NOPAT works out to roughly ₹191 crore. Capitalised at the 12% WACC and adding back net cash of ₹524 crore, EPV equity value comes to approximately ₹2,118 crore, or ~₹65 per share.

The gap between this ₹65 EPV floor and the ₹479 CMP is stark — it quantifies just how much of the current price is a bet on future growth and margin expansion rather than today’s demonstrated earnings power. This is normal and expected for a business scaling as fast as Honasa is, but it also means any stumble in the growth trajectory carries outsized downside risk to the share price.

Valuing the Portfolio Brand-by-Brand

Honasa’s brands sit at very different maturity stages, which a blended multiple obscures. We split the portfolio into three tiers and apply differentiated EV/Sales multiples reflecting growth and margin profile.

Even crediting The Derma Co. with a rich 6.5x sales multiple in recognition of its superior growth and margin trajectory, SOTP arrives at ~₹325/share — meaningfully below CMP, though above the pure DCF and well above the EPV floor, consistent with a market that is paying up specifically for the Derma Co./younger-brands growth optionality.

Accumulation Zones

Our blended fair value (weighting DCF, SOTP and peer EV/Sales) clusters around ₹375–₹400. A meaningful, valuation-driven pullback toward the ₹280–₹340 band — which has precedent given the stock’s 45% correction earlier in 2026 — would offer a materially better entry point for long-term holders who believe in the FY31 revenue and margin story.

What Has to Go Right

Distribution Zones

At CMP of ₹479, the stock sits squarely inside the Reduce zone. It is trading at a 78x trailing and ~53x FY27E P/E — multiples that leave very little room for execution slippage. Existing holders with substantial gains (the stock is up ~78% over the past year and ~192% from its 52-week low) may consider booking partial profits into strength, particularly on any push toward the ₹490-520 all-time-high zone.

What Would Trigger an Exit

The FY31 Roadmap

Management’s June 2026 Investor Day guidance targets ₹5,500 crore of revenue by FY31 (~18% CAGR from FY26), anchored on: continued teens-plus growth at Mamaearth as it completes its turnaround; The Derma Co. scaling well beyond its current ₹1,000+ crore ARR as India’s leading digital-first dermatology-inspired skincare brand; younger brands (Aqualogica, BBlunt, Dr Sheth’s, Staze) and BTM Ventures graduating from the >₹150 crore ARR stage into meaningful scale; and continued build-out of general trade and modern trade distribution, which is still under 3 lakh outlets versus a multi-million outlet FMCG universe.

On margins, management has guided to roughly 100 bps of EBITDA margin expansion annually, driven by advertising spend growing slower than revenue (already visible in Q1 FY27, where ad-spend-to-sales fell from 34.6% to 31.8% YoY) and operating leverage across employee and overhead costs.

Balancing the Scorecard